nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Naftifine—Diphenhydramine—atopic dermatitis	0.333	0.614	CrCrCtD
Duloxetine—Atomoxetine—Diphenhydramine—atopic dermatitis	0.209	0.386	CrCrCtD
Duloxetine—CYP1A2—Diphenhydramine—atopic dermatitis	0.0185	0.341	CbGbCtD
Duloxetine—CYP2D6—Loratadine—atopic dermatitis	0.0152	0.281	CbGbCtD
Duloxetine—CYP2D6—Diphenhydramine—atopic dermatitis	0.0152	0.281	CbGbCtD
Duloxetine—CYP2D6—Dexamethasone—atopic dermatitis	0.00527	0.0972	CbGbCtD
Duloxetine—HTR2A—GPCR ligand binding—CCL17—atopic dermatitis	0.000153	0.00213	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000152	0.00211	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL27—atopic dermatitis	0.00015	0.0021	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—STAT6—atopic dermatitis	0.000149	0.00207	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCL5—atopic dermatitis	0.000146	0.00204	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—BDNF—atopic dermatitis	0.000146	0.00203	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000146	0.00203	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL11—atopic dermatitis	0.000142	0.00197	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL8—atopic dermatitis	0.000141	0.00196	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—NPS—atopic dermatitis	0.00014	0.00195	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—TAC1—atopic dermatitis	0.00014	0.00195	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—atopic dermatitis	0.000139	0.00194	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCR3—atopic dermatitis	0.000137	0.00191	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL27—atopic dermatitis	0.000137	0.0019	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000135	0.00188	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000135	0.00188	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CXCR3—atopic dermatitis	0.000134	0.00187	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CCL5—atopic dermatitis	0.000133	0.00185	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000133	0.00185	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	0.000132	0.00184	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR3—atopic dermatitis	0.000132	0.00184	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCR5—atopic dermatitis	0.000132	0.00183	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NGF—atopic dermatitis	0.00013	0.0018	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR3—atopic dermatitis	0.000129	0.0018	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	0.000127	0.00176	CbGpPWpGaD
Duloxetine—Headache—Tacrolimus—atopic dermatitis	0.000126	0.000379	CcSEcCtD
Duloxetine—Anaphylactic shock—Hydrocortisone—atopic dermatitis	0.000125	0.000378	CcSEcCtD
Duloxetine—Oedema—Hydrocortisone—atopic dermatitis	0.000125	0.000378	CcSEcCtD
Duloxetine—Convulsion—Triamcinolone—atopic dermatitis	0.000125	0.000378	CcSEcCtD
Duloxetine—Tachycardia—Prednisolone—atopic dermatitis	0.000125	0.000378	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	0.000125	0.00175	CbGpPWpGaD
Duloxetine—Convulsion—Methylprednisolone—atopic dermatitis	0.000125	0.000377	CcSEcCtD
Duloxetine—Hypertension—Triamcinolone—atopic dermatitis	0.000125	0.000376	CcSEcCtD
Duloxetine—Hypertension—Methylprednisolone—atopic dermatitis	0.000125	0.000375	CcSEcCtD
Duloxetine—Infection—Hydrocortisone—atopic dermatitis	0.000125	0.000375	CcSEcCtD
Duloxetine—Hyperhidrosis—Prednisolone—atopic dermatitis	0.000124	0.000374	CcSEcCtD
Duloxetine—Shock—Hydrocortisone—atopic dermatitis	0.000123	0.000372	CcSEcCtD
Duloxetine—Myalgia—Triamcinolone—atopic dermatitis	0.000123	0.000371	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCL11—atopic dermatitis	0.000123	0.00171	CbGpPWpGaD
Duloxetine—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000123	0.00037	CcSEcCtD
Duloxetine—Myalgia—Methylprednisolone—atopic dermatitis	0.000123	0.00037	CcSEcCtD
Duloxetine—Arthralgia—Methylprednisolone—atopic dermatitis	0.000123	0.00037	CcSEcCtD
Duloxetine—Eye disorder—Prednisone—atopic dermatitis	0.000123	0.00037	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CCL17—atopic dermatitis	0.000123	0.00171	CbGpPWpGaD
Duloxetine—Anxiety—Methylprednisolone—atopic dermatitis	0.000123	0.000369	CcSEcCtD
Duloxetine—Tachycardia—Hydrocortisone—atopic dermatitis	0.000122	0.000369	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000122	0.000368	CcSEcCtD
Duloxetine—Flushing—Prednisone—atopic dermatitis	0.000122	0.000367	CcSEcCtD
Duloxetine—Skin disorder—Hydrocortisone—atopic dermatitis	0.000122	0.000367	CcSEcCtD
Duloxetine—Ill-defined disorder—Dexamethasone—atopic dermatitis	0.000122	0.000367	CcSEcCtD
Duloxetine—Ill-defined disorder—Betamethasone—atopic dermatitis	0.000122	0.000367	CcSEcCtD
Duloxetine—Discomfort—Triamcinolone—atopic dermatitis	0.000122	0.000367	CcSEcCtD
Duloxetine—Discomfort—Methylprednisolone—atopic dermatitis	0.000121	0.000366	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	0.000121	0.00169	CbGpPWpGaD
Duloxetine—Hyperhidrosis—Hydrocortisone—atopic dermatitis	0.000121	0.000365	CcSEcCtD
Duloxetine—Dry mouth—Triamcinolone—atopic dermatitis	0.000121	0.000363	CcSEcCtD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.00012	0.00168	CbGpPWpGaD
Duloxetine—Angioedema—Dexamethasone—atopic dermatitis	0.00012	0.000361	CcSEcCtD
Duloxetine—Angioedema—Betamethasone—atopic dermatitis	0.00012	0.000361	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—CCR5—atopic dermatitis	0.00012	0.00167	CbGpPWpGaD
Duloxetine—Anorexia—Hydrocortisone—atopic dermatitis	0.00012	0.00036	CcSEcCtD
Duloxetine—Nausea—Tacrolimus—atopic dermatitis	0.000119	0.00036	CcSEcCtD
Duloxetine—Angiopathy—Prednisone—atopic dermatitis	0.000119	0.000359	CcSEcCtD
Duloxetine—Confusional state—Methylprednisolone—atopic dermatitis	0.000119	0.000358	CcSEcCtD
Duloxetine—Immune system disorder—Prednisone—atopic dermatitis	0.000119	0.000357	CcSEcCtD
Duloxetine—Malaise—Betamethasone—atopic dermatitis	0.000118	0.000357	CcSEcCtD
Duloxetine—Malaise—Dexamethasone—atopic dermatitis	0.000118	0.000357	CcSEcCtD
Duloxetine—Anaphylactic shock—Triamcinolone—atopic dermatitis	0.000118	0.000356	CcSEcCtD
Duloxetine—Oedema—Triamcinolone—atopic dermatitis	0.000118	0.000356	CcSEcCtD
Duloxetine—Vertigo—Betamethasone—atopic dermatitis	0.000118	0.000355	CcSEcCtD
Duloxetine—Vertigo—Dexamethasone—atopic dermatitis	0.000118	0.000355	CcSEcCtD
Duloxetine—Anaphylactic shock—Methylprednisolone—atopic dermatitis	0.000118	0.000355	CcSEcCtD
Duloxetine—Syncope—Dexamethasone—atopic dermatitis	0.000118	0.000355	CcSEcCtD
Duloxetine—Syncope—Betamethasone—atopic dermatitis	0.000118	0.000355	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—NPS—atopic dermatitis	0.000117	0.00164	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—TAC1—atopic dermatitis	0.000117	0.00164	CbGpPWpGaD
Duloxetine—Arrhythmia—Prednisone—atopic dermatitis	0.000117	0.000353	CcSEcCtD
Duloxetine—Infection—Triamcinolone—atopic dermatitis	0.000117	0.000353	CcSEcCtD
Duloxetine—Infection—Methylprednisolone—atopic dermatitis	0.000117	0.000353	CcSEcCtD
Duloxetine—Shock—Triamcinolone—atopic dermatitis	0.000116	0.00035	CcSEcCtD
Duloxetine—Insomnia—Prednisolone—atopic dermatitis	0.000116	0.00035	CcSEcCtD
Duloxetine—Alopecia—Prednisone—atopic dermatitis	0.000116	0.00035	CcSEcCtD
Duloxetine—Shock—Methylprednisolone—atopic dermatitis	0.000116	0.000349	CcSEcCtD
Duloxetine—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000116	0.000348	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CCR3—atopic dermatitis	0.000116	0.00161	CbGpPWpGaD
Duloxetine—Loss of consciousness—Dexamethasone—atopic dermatitis	0.000115	0.000348	CcSEcCtD
Duloxetine—Loss of consciousness—Betamethasone—atopic dermatitis	0.000115	0.000348	CcSEcCtD
Duloxetine—Paraesthesia—Prednisolone—atopic dermatitis	0.000115	0.000347	CcSEcCtD
Duloxetine—Tachycardia—Triamcinolone—atopic dermatitis	0.000115	0.000347	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—atopic dermatitis	0.000115	0.0016	CbGpPWpGaD
Duloxetine—Mental disorder—Prednisone—atopic dermatitis	0.000115	0.000347	CcSEcCtD
Duloxetine—Tachycardia—Methylprednisolone—atopic dermatitis	0.000115	0.000346	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—NPS—atopic dermatitis	0.000115	0.0016	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TAC1—atopic dermatitis	0.000115	0.0016	CbGpPWpGaD
Duloxetine—Skin disorder—Methylprednisolone—atopic dermatitis	0.000115	0.000345	CcSEcCtD
Duloxetine—Erythema—Prednisone—atopic dermatitis	0.000114	0.000344	CcSEcCtD
Duloxetine—Malnutrition—Prednisone—atopic dermatitis	0.000114	0.000344	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000114	0.000344	CcSEcCtD
Duloxetine—Hyperhidrosis—Triamcinolone—atopic dermatitis	0.000114	0.000344	CcSEcCtD
Duloxetine—Hyperhidrosis—Methylprednisolone—atopic dermatitis	0.000114	0.000343	CcSEcCtD
Duloxetine—Convulsion—Betamethasone—atopic dermatitis	0.000114	0.000343	CcSEcCtD
Duloxetine—Convulsion—Dexamethasone—atopic dermatitis	0.000114	0.000343	CcSEcCtD
Duloxetine—Insomnia—Hydrocortisone—atopic dermatitis	0.000113	0.000342	CcSEcCtD
Duloxetine—Hypertension—Betamethasone—atopic dermatitis	0.000113	0.000341	CcSEcCtD
Duloxetine—Hypertension—Dexamethasone—atopic dermatitis	0.000113	0.000341	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	0.000113	0.00157	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL22—atopic dermatitis	0.000113	0.00157	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCR3—atopic dermatitis	0.000113	0.00157	CbGpPWpGaD
Duloxetine—Paraesthesia—Hydrocortisone—atopic dermatitis	0.000113	0.000339	CcSEcCtD
Duloxetine—Myalgia—Betamethasone—atopic dermatitis	0.000112	0.000337	CcSEcCtD
Duloxetine—Myalgia—Dexamethasone—atopic dermatitis	0.000112	0.000337	CcSEcCtD
Duloxetine—Anxiety—Dexamethasone—atopic dermatitis	0.000111	0.000336	CcSEcCtD
Duloxetine—Anxiety—Betamethasone—atopic dermatitis	0.000111	0.000336	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CXCL10—atopic dermatitis	0.000111	0.00154	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL27—atopic dermatitis	0.000111	0.00154	CbGpPWpGaD
Duloxetine—Discomfort—Betamethasone—atopic dermatitis	0.00011	0.000333	CcSEcCtD
Duloxetine—Discomfort—Dexamethasone—atopic dermatitis	0.00011	0.000333	CcSEcCtD
Duloxetine—Dyspepsia—Hydrocortisone—atopic dermatitis	0.00011	0.000333	CcSEcCtD
Duloxetine—Pain—Prednisolone—atopic dermatitis	0.00011	0.000331	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—atopic dermatitis	0.000109	0.00152	CbGpPWpGaD
Duloxetine—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000109	0.000328	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.000108	0.000326	CcSEcCtD
Duloxetine—Fatigue—Hydrocortisone—atopic dermatitis	0.000108	0.000326	CcSEcCtD
Duloxetine—Vision blurred—Prednisone—atopic dermatitis	0.000108	0.000325	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000108	0.000324	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—Pain—Hydrocortisone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	0.000107	0.00149	CbGpPWpGaD
Duloxetine—Oedema—Dexamethasone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—Anaphylactic shock—Dexamethasone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—Anaphylactic shock—Betamethasone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—Oedema—Betamethasone—atopic dermatitis	0.000107	0.000323	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—IL5—atopic dermatitis	0.000107	0.00149	CbGpPWpGaD
Duloxetine—Insomnia—Triamcinolone—atopic dermatitis	0.000107	0.000322	CcSEcCtD
Duloxetine—Insomnia—Methylprednisolone—atopic dermatitis	0.000107	0.000321	CcSEcCtD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	0.000107	0.00148	CbGpPWpGaD
Duloxetine—Infection—Dexamethasone—atopic dermatitis	0.000106	0.000321	CcSEcCtD
Duloxetine—Infection—Betamethasone—atopic dermatitis	0.000106	0.000321	CcSEcCtD
Duloxetine—Ill-defined disorder—Prednisone—atopic dermatitis	0.000106	0.00032	CcSEcCtD
Duloxetine—Paraesthesia—Triamcinolone—atopic dermatitis	0.000106	0.000319	CcSEcCtD
Duloxetine—Feeling abnormal—Prednisolone—atopic dermatitis	0.000106	0.000319	CcSEcCtD
Duloxetine—Paraesthesia—Methylprednisolone—atopic dermatitis	0.000106	0.000319	CcSEcCtD
Duloxetine—Anaemia—Prednisone—atopic dermatitis	0.000106	0.000318	CcSEcCtD
Duloxetine—Shock—Dexamethasone—atopic dermatitis	0.000105	0.000318	CcSEcCtD
Duloxetine—Shock—Betamethasone—atopic dermatitis	0.000105	0.000318	CcSEcCtD
Duloxetine—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000105	0.000317	CcSEcCtD
Duloxetine—Nervous system disorder—Betamethasone—atopic dermatitis	0.000105	0.000317	CcSEcCtD
Duloxetine—Agitation—Prednisone—atopic dermatitis	0.000105	0.000316	CcSEcCtD
Duloxetine—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000105	0.000316	CcSEcCtD
Duloxetine—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000105	0.000316	CcSEcCtD
Duloxetine—Tachycardia—Dexamethasone—atopic dermatitis	0.000105	0.000315	CcSEcCtD
Duloxetine—Tachycardia—Betamethasone—atopic dermatitis	0.000105	0.000315	CcSEcCtD
Duloxetine—Angioedema—Prednisone—atopic dermatitis	0.000105	0.000315	CcSEcCtD
Duloxetine—Dyspepsia—Triamcinolone—atopic dermatitis	0.000104	0.000313	CcSEcCtD
Duloxetine—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000104	0.000312	CcSEcCtD
Duloxetine—Hyperhidrosis—Dexamethasone—atopic dermatitis	0.000104	0.000312	CcSEcCtD
Duloxetine—Hyperhidrosis—Betamethasone—atopic dermatitis	0.000104	0.000312	CcSEcCtD
Duloxetine—Feeling abnormal—Hydrocortisone—atopic dermatitis	0.000103	0.000311	CcSEcCtD
Duloxetine—Malaise—Prednisone—atopic dermatitis	0.000103	0.000311	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—TAC1—atopic dermatitis	0.000103	0.00143	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—NPS—atopic dermatitis	0.000103	0.00143	CbGpPWpGaD
Duloxetine—Vertigo—Prednisone—atopic dermatitis	0.000103	0.000309	CcSEcCtD
Duloxetine—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000103	0.000309	CcSEcCtD
Duloxetine—Syncope—Prednisone—atopic dermatitis	0.000103	0.000309	CcSEcCtD
Duloxetine—Anorexia—Betamethasone—atopic dermatitis	0.000102	0.000308	CcSEcCtD
Duloxetine—Anorexia—Dexamethasone—atopic dermatitis	0.000102	0.000308	CcSEcCtD
Duloxetine—Urticaria—Prednisolone—atopic dermatitis	0.000102	0.000307	CcSEcCtD
Duloxetine—Fatigue—Triamcinolone—atopic dermatitis	0.000102	0.000307	CcSEcCtD
Duloxetine—Fatigue—Methylprednisolone—atopic dermatitis	0.000102	0.000306	CcSEcCtD
Duloxetine—Pain—Triamcinolone—atopic dermatitis	0.000101	0.000304	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CXCR3—atopic dermatitis	0.000101	0.00141	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL27—atopic dermatitis	0.000101	0.0014	CbGpPWpGaD
Duloxetine—Loss of consciousness—Prednisone—atopic dermatitis	0.000101	0.000303	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCR3—atopic dermatitis	0.0001	0.0014	CbGpPWpGaD
Duloxetine—Urticaria—Hydrocortisone—atopic dermatitis	9.97e-05	0.0003	CcSEcCtD
Duloxetine—Body temperature increased—Hydrocortisone—atopic dermatitis	9.92e-05	0.000299	CcSEcCtD
Duloxetine—Abdominal pain—Hydrocortisone—atopic dermatitis	9.92e-05	0.000299	CcSEcCtD
Duloxetine—Convulsion—Prednisone—atopic dermatitis	9.91e-05	0.000298	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CCL11—atopic dermatitis	9.88e-05	0.00138	CbGpPWpGaD
Duloxetine—Hypertension—Prednisone—atopic dermatitis	9.88e-05	0.000297	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—CCL22—atopic dermatitis	9.8e-05	0.00137	CbGpPWpGaD
Duloxetine—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	9.77e-05	0.000294	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	9.77e-05	0.000294	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—atopic dermatitis	9.75e-05	0.00136	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FCER2—atopic dermatitis	9.74e-05	0.00136	CbGpPWpGaD
Duloxetine—Myalgia—Prednisone—atopic dermatitis	9.74e-05	0.000293	CcSEcCtD
Duloxetine—Arthralgia—Prednisone—atopic dermatitis	9.74e-05	0.000293	CcSEcCtD
Duloxetine—Feeling abnormal—Triamcinolone—atopic dermatitis	9.74e-05	0.000293	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—atopic dermatitis	9.72e-05	0.00135	CbGpPWpGaD
Duloxetine—Feeling abnormal—Methylprednisolone—atopic dermatitis	9.71e-05	0.000292	CcSEcCtD
Duloxetine—Anxiety—Prednisone—atopic dermatitis	9.7e-05	0.000292	CcSEcCtD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	9.7e-05	0.00135	CbGpPWpGaD
Duloxetine—Insomnia—Betamethasone—atopic dermatitis	9.7e-05	0.000292	CcSEcCtD
Duloxetine—Insomnia—Dexamethasone—atopic dermatitis	9.7e-05	0.000292	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	9.67e-05	0.000291	CcSEcCtD
Duloxetine—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	9.64e-05	0.00029	CcSEcCtD
Duloxetine—Paraesthesia—Betamethasone—atopic dermatitis	9.63e-05	0.00029	CcSEcCtD
Duloxetine—Paraesthesia—Dexamethasone—atopic dermatitis	9.63e-05	0.00029	CcSEcCtD
Duloxetine—HTR2A—GPCR downstream signaling—CCL27—atopic dermatitis	9.62e-05	0.00134	CbGpPWpGaD
Duloxetine—Discomfort—Prednisone—atopic dermatitis	9.62e-05	0.00029	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CCL5—atopic dermatitis	9.54e-05	0.00133	CbGpPWpGaD
Duloxetine—Hypersensitivity—Prednisolone—atopic dermatitis	9.47e-05	0.000285	CcSEcCtD
Duloxetine—Dyspepsia—Dexamethasone—atopic dermatitis	9.44e-05	0.000284	CcSEcCtD
Duloxetine—Dyspepsia—Betamethasone—atopic dermatitis	9.44e-05	0.000284	CcSEcCtD
Duloxetine—Urticaria—Triamcinolone—atopic dermatitis	9.39e-05	0.000283	CcSEcCtD
Duloxetine—Urticaria—Methylprednisolone—atopic dermatitis	9.36e-05	0.000282	CcSEcCtD
Duloxetine—Body temperature increased—Triamcinolone—atopic dermatitis	9.34e-05	0.000281	CcSEcCtD
Duloxetine—Anaphylactic shock—Prednisone—atopic dermatitis	9.34e-05	0.000281	CcSEcCtD
Duloxetine—Oedema—Prednisone—atopic dermatitis	9.34e-05	0.000281	CcSEcCtD
Duloxetine—Abdominal pain—Methylprednisolone—atopic dermatitis	9.32e-05	0.000281	CcSEcCtD
Duloxetine—Decreased appetite—Dexamethasone—atopic dermatitis	9.32e-05	0.000281	CcSEcCtD
Duloxetine—Decreased appetite—Betamethasone—atopic dermatitis	9.32e-05	0.000281	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—atopic dermatitis	9.31e-05	0.0013	CbGpPWpGaD
Duloxetine—Infection—Prednisone—atopic dermatitis	9.27e-05	0.000279	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	9.25e-05	0.000279	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Betamethasone—atopic dermatitis	9.25e-05	0.000279	CcSEcCtD
Duloxetine—Hypersensitivity—Hydrocortisone—atopic dermatitis	9.24e-05	0.000278	CcSEcCtD
Duloxetine—Fatigue—Dexamethasone—atopic dermatitis	9.24e-05	0.000278	CcSEcCtD
Duloxetine—Fatigue—Betamethasone—atopic dermatitis	9.24e-05	0.000278	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	9.23e-05	0.00129	CbGpPWpGaD
Duloxetine—Shock—Prednisone—atopic dermatitis	9.18e-05	0.000277	CcSEcCtD
Duloxetine—Pain—Betamethasone—atopic dermatitis	9.17e-05	0.000276	CcSEcCtD
Duloxetine—Pain—Dexamethasone—atopic dermatitis	9.17e-05	0.000276	CcSEcCtD
Duloxetine—Nervous system disorder—Prednisone—atopic dermatitis	9.16e-05	0.000276	CcSEcCtD
Duloxetine—Tachycardia—Prednisone—atopic dermatitis	9.11e-05	0.000274	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CXCL10—atopic dermatitis	9.11e-05	0.00127	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—MAPK8—atopic dermatitis	9.09e-05	0.00127	CbGpPWpGaD
Duloxetine—Skin disorder—Prednisone—atopic dermatitis	9.07e-05	0.000273	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CCL22—atopic dermatitis	9.06e-05	0.00126	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL17—atopic dermatitis	9.03e-05	0.00126	CbGpPWpGaD
Duloxetine—Hyperhidrosis—Prednisone—atopic dermatitis	9.03e-05	0.000272	CcSEcCtD
Duloxetine—Asthenia—Hydrocortisone—atopic dermatitis	9e-05	0.000271	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—TAC1—atopic dermatitis	8.94e-05	0.00125	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—NPS—atopic dermatitis	8.94e-05	0.00125	CbGpPWpGaD
Duloxetine—Anorexia—Prednisone—atopic dermatitis	8.9e-05	0.000268	CcSEcCtD
Duloxetine—Pruritus—Hydrocortisone—atopic dermatitis	8.88e-05	0.000267	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—CCR3—atopic dermatitis	8.87e-05	0.00124	CbGpPWpGaD
Duloxetine—Feeling abnormal—Betamethasone—atopic dermatitis	8.83e-05	0.000266	CcSEcCtD
Duloxetine—Feeling abnormal—Dexamethasone—atopic dermatitis	8.83e-05	0.000266	CcSEcCtD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—atopic dermatitis	8.81e-05	0.00123	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCR3—atopic dermatitis	8.77e-05	0.00122	CbGpPWpGaD
Duloxetine—Gastrointestinal pain—Betamethasone—atopic dermatitis	8.77e-05	0.000264	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dexamethasone—atopic dermatitis	8.77e-05	0.000264	CcSEcCtD
Duloxetine—HTR2A—Signaling by GPCR—CCL27—atopic dermatitis	8.74e-05	0.00122	CbGpPWpGaD
Duloxetine—Hypersensitivity—Triamcinolone—atopic dermatitis	8.7e-05	0.000262	CcSEcCtD
Duloxetine—Hypersensitivity—Methylprednisolone—atopic dermatitis	8.69e-05	0.000261	CcSEcCtD
Duloxetine—HTR6—GPCR ligand binding—CCR5—atopic dermatitis	8.6e-05	0.0012	CbGpPWpGaD
Duloxetine—Diarrhoea—Hydrocortisone—atopic dermatitis	8.58e-05	0.000258	CcSEcCtD
Duloxetine—Urticaria—Dexamethasone—atopic dermatitis	8.52e-05	0.000256	CcSEcCtD
Duloxetine—Urticaria—Betamethasone—atopic dermatitis	8.52e-05	0.000256	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Prednisone—atopic dermatitis	8.51e-05	0.000256	CcSEcCtD
Duloxetine—Dizziness—Prednisolone—atopic dermatitis	8.5e-05	0.000256	CcSEcCtD
Duloxetine—Asthenia—Triamcinolone—atopic dermatitis	8.48e-05	0.000255	CcSEcCtD
Duloxetine—Abdominal pain—Dexamethasone—atopic dermatitis	8.47e-05	0.000255	CcSEcCtD
Duloxetine—Body temperature increased—Betamethasone—atopic dermatitis	8.47e-05	0.000255	CcSEcCtD
Duloxetine—Body temperature increased—Dexamethasone—atopic dermatitis	8.47e-05	0.000255	CcSEcCtD
Duloxetine—Abdominal pain—Betamethasone—atopic dermatitis	8.47e-05	0.000255	CcSEcCtD
Duloxetine—Asthenia—Methylprednisolone—atopic dermatitis	8.46e-05	0.000255	CcSEcCtD
Duloxetine—Insomnia—Prednisone—atopic dermatitis	8.44e-05	0.000254	CcSEcCtD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—atopic dermatitis	8.43e-05	0.00117	CbGpPWpGaD
Duloxetine—Paraesthesia—Prednisone—atopic dermatitis	8.38e-05	0.000252	CcSEcCtD
Duloxetine—Pruritus—Triamcinolone—atopic dermatitis	8.36e-05	0.000252	CcSEcCtD
Duloxetine—Pruritus—Methylprednisolone—atopic dermatitis	8.34e-05	0.000251	CcSEcCtD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	8.31e-05	0.00116	CbGpPWpGaD
Duloxetine—Dizziness—Hydrocortisone—atopic dermatitis	8.3e-05	0.00025	CcSEcCtD
Duloxetine—Dyspepsia—Prednisone—atopic dermatitis	8.22e-05	0.000247	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CXCL10—atopic dermatitis	8.16e-05	0.00114	CbGpPWpGaD
Duloxetine—Decreased appetite—Prednisone—atopic dermatitis	8.12e-05	0.000244	CcSEcCtD
Duloxetine—Rash—Prednisolone—atopic dermatitis	8.1e-05	0.000244	CcSEcCtD
Duloxetine—Dermatitis—Prednisolone—atopic dermatitis	8.09e-05	0.000244	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CCL27—atopic dermatitis	8.07e-05	0.00112	CbGpPWpGaD
Duloxetine—Diarrhoea—Methylprednisolone—atopic dermatitis	8.07e-05	0.000243	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—CCR3—atopic dermatitis	8.05e-05	0.00112	CbGpPWpGaD
Duloxetine—Fatigue—Prednisone—atopic dermatitis	8.05e-05	0.000242	CcSEcCtD
Duloxetine—Headache—Prednisolone—atopic dermatitis	8.05e-05	0.000242	CcSEcCtD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL5—atopic dermatitis	8.01e-05	0.00112	CbGpPWpGaD
Duloxetine—Constipation—Prednisone—atopic dermatitis	7.98e-05	0.00024	CcSEcCtD
Duloxetine—Vomiting—Hydrocortisone—atopic dermatitis	7.98e-05	0.00024	CcSEcCtD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL8—atopic dermatitis	7.96e-05	0.00111	CbGpPWpGaD
Duloxetine—Rash—Hydrocortisone—atopic dermatitis	7.91e-05	0.000238	CcSEcCtD
Duloxetine—Dermatitis—Hydrocortisone—atopic dermatitis	7.9e-05	0.000238	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—NPS—atopic dermatitis	7.9e-05	0.0011	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—TAC1—atopic dermatitis	7.9e-05	0.0011	CbGpPWpGaD
Duloxetine—Headache—Hydrocortisone—atopic dermatitis	7.86e-05	0.000237	CcSEcCtD
Duloxetine—NPY1R—Signaling Pathways—CCL5—atopic dermatitis	7.84e-05	0.00109	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL17—atopic dermatitis	7.84e-05	0.00109	CbGpPWpGaD
Duloxetine—Dizziness—Triamcinolone—atopic dermatitis	7.81e-05	0.000235	CcSEcCtD
Duloxetine—Dizziness—Methylprednisolone—atopic dermatitis	7.8e-05	0.000235	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—CXCR3—atopic dermatitis	7.75e-05	0.00108	CbGpPWpGaD
Duloxetine—Feeling abnormal—Prednisone—atopic dermatitis	7.69e-05	0.000232	CcSEcCtD
Duloxetine—Asthenia—Betamethasone—atopic dermatitis	7.69e-05	0.000232	CcSEcCtD
Duloxetine—Asthenia—Dexamethasone—atopic dermatitis	7.69e-05	0.000232	CcSEcCtD
Duloxetine—Gastrointestinal pain—Prednisone—atopic dermatitis	7.63e-05	0.00023	CcSEcCtD
Duloxetine—Nausea—Prednisolone—atopic dermatitis	7.63e-05	0.00023	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	7.62e-05	0.00106	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—atopic dermatitis	7.61e-05	0.00106	CbGpPWpGaD
Duloxetine—Pruritus—Dexamethasone—atopic dermatitis	7.58e-05	0.000228	CcSEcCtD
Duloxetine—Pruritus—Betamethasone—atopic dermatitis	7.58e-05	0.000228	CcSEcCtD
Duloxetine—Vomiting—Triamcinolone—atopic dermatitis	7.51e-05	0.000226	CcSEcCtD
Duloxetine—Vomiting—Methylprednisolone—atopic dermatitis	7.5e-05	0.000226	CcSEcCtD
Duloxetine—Nausea—Hydrocortisone—atopic dermatitis	7.45e-05	0.000224	CcSEcCtD
Duloxetine—Rash—Triamcinolone—atopic dermatitis	7.45e-05	0.000224	CcSEcCtD
Duloxetine—Dermatitis—Triamcinolone—atopic dermatitis	7.44e-05	0.000224	CcSEcCtD
Duloxetine—Rash—Methylprednisolone—atopic dermatitis	7.43e-05	0.000224	CcSEcCtD
Duloxetine—Dermatitis—Methylprednisolone—atopic dermatitis	7.43e-05	0.000224	CcSEcCtD
Duloxetine—Urticaria—Prednisone—atopic dermatitis	7.42e-05	0.000223	CcSEcCtD
Duloxetine—Headache—Triamcinolone—atopic dermatitis	7.4e-05	0.000223	CcSEcCtD
Duloxetine—Headache—Methylprednisolone—atopic dermatitis	7.38e-05	0.000222	CcSEcCtD
Duloxetine—Abdominal pain—Prednisone—atopic dermatitis	7.38e-05	0.000222	CcSEcCtD
Duloxetine—Body temperature increased—Prednisone—atopic dermatitis	7.38e-05	0.000222	CcSEcCtD
Duloxetine—HTR6—GPCR downstream signaling—IL5—atopic dermatitis	7.35e-05	0.00102	CbGpPWpGaD
Duloxetine—Diarrhoea—Dexamethasone—atopic dermatitis	7.33e-05	0.000221	CcSEcCtD
Duloxetine—Diarrhoea—Betamethasone—atopic dermatitis	7.33e-05	0.000221	CcSEcCtD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	7.31e-05	0.00102	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL11—atopic dermatitis	7.27e-05	0.00101	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NGF—atopic dermatitis	7.26e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL17—atopic dermatitis	7.24e-05	0.00101	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL8—atopic dermatitis	7.23e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—atopic dermatitis	7.22e-05	0.00101	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—TAC1—atopic dermatitis	7.18e-05	0.001	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NPS—atopic dermatitis	7.18e-05	0.001	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FCER2—atopic dermatitis	7.17e-05	0.000999	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—atopic dermatitis	7.11e-05	0.000991	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL10—atopic dermatitis	7.09e-05	0.000988	CbGpPWpGaD
Duloxetine—Dizziness—Dexamethasone—atopic dermatitis	7.09e-05	0.000213	CcSEcCtD
Duloxetine—Dizziness—Betamethasone—atopic dermatitis	7.09e-05	0.000213	CcSEcCtD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	7.08e-05	0.000986	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	7.08e-05	0.000986	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR5—atopic dermatitis	7.07e-05	0.000984	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCR3—atopic dermatitis	7.04e-05	0.00098	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCL5—atopic dermatitis	7.03e-05	0.000979	CbGpPWpGaD
Duloxetine—Nausea—Triamcinolone—atopic dermatitis	7.02e-05	0.000211	CcSEcCtD
Duloxetine—Nausea—Methylprednisolone—atopic dermatitis	7e-05	0.000211	CcSEcCtD
Duloxetine—NPY1R—Signaling by GPCR—IL2—atopic dermatitis	6.91e-05	0.000963	CbGpPWpGaD
Duloxetine—Hypersensitivity—Prednisone—atopic dermatitis	6.88e-05	0.000207	CcSEcCtD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	6.83e-05	0.000951	CbGpPWpGaD
Duloxetine—Vomiting—Betamethasone—atopic dermatitis	6.82e-05	0.000205	CcSEcCtD
Duloxetine—Vomiting—Dexamethasone—atopic dermatitis	6.82e-05	0.000205	CcSEcCtD
Duloxetine—Rash—Dexamethasone—atopic dermatitis	6.76e-05	0.000203	CcSEcCtD
Duloxetine—Rash—Betamethasone—atopic dermatitis	6.76e-05	0.000203	CcSEcCtD
Duloxetine—Dermatitis—Dexamethasone—atopic dermatitis	6.75e-05	0.000203	CcSEcCtD
Duloxetine—Dermatitis—Betamethasone—atopic dermatitis	6.75e-05	0.000203	CcSEcCtD
Duloxetine—Headache—Betamethasone—atopic dermatitis	6.72e-05	0.000202	CcSEcCtD
Duloxetine—Headache—Dexamethasone—atopic dermatitis	6.72e-05	0.000202	CcSEcCtD
Duloxetine—Asthenia—Prednisone—atopic dermatitis	6.7e-05	0.000202	CcSEcCtD
Duloxetine—HTR6—Signaling by GPCR—IL5—atopic dermatitis	6.67e-05	0.000929	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL22—atopic dermatitis	6.67e-05	0.000929	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	6.64e-05	0.000925	CbGpPWpGaD
Duloxetine—Pruritus—Prednisone—atopic dermatitis	6.6e-05	0.000199	CcSEcCtD
Duloxetine—HTR2C—GPCR downstream signaling—CCR3—atopic dermatitis	6.53e-05	0.00091	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KIF3A—atopic dermatitis	6.45e-05	0.000899	CbGpPWpGaD
Duloxetine—Diarrhoea—Prednisone—atopic dermatitis	6.39e-05	0.000192	CcSEcCtD
Duloxetine—Nausea—Betamethasone—atopic dermatitis	6.37e-05	0.000192	CcSEcCtD
Duloxetine—Nausea—Dexamethasone—atopic dermatitis	6.37e-05	0.000192	CcSEcCtD
Duloxetine—HTR2C—GPCR ligand binding—CCR5—atopic dermatitis	6.33e-05	0.000882	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL11—atopic dermatitis	6.32e-05	0.00088	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL10—atopic dermatitis	6.27e-05	0.000873	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FCER2—atopic dermatitis	6.23e-05	0.000868	CbGpPWpGaD
Duloxetine—Dizziness—Prednisone—atopic dermatitis	6.17e-05	0.000186	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCL5—atopic dermatitis	6.1e-05	0.00085	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NFKBIA—atopic dermatitis	5.99e-05	0.000834	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL27—atopic dermatitis	5.94e-05	0.000828	CbGpPWpGaD
Duloxetine—Vomiting—Prednisone—atopic dermatitis	5.94e-05	0.000179	CcSEcCtD
Duloxetine—HTR2C—Signaling by GPCR—CCR3—atopic dermatitis	5.93e-05	0.000826	CbGpPWpGaD
Duloxetine—Rash—Prednisone—atopic dermatitis	5.89e-05	0.000177	CcSEcCtD
Duloxetine—Dermatitis—Prednisone—atopic dermatitis	5.88e-05	0.000177	CcSEcCtD
Duloxetine—Headache—Prednisone—atopic dermatitis	5.85e-05	0.000176	CcSEcCtD
Duloxetine—HTR6—Signaling Pathways—CCL11—atopic dermatitis	5.84e-05	0.000813	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CMA1—atopic dermatitis	5.84e-05	0.000813	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	5.83e-05	0.000812	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—NPS—atopic dermatitis	5.82e-05	0.000811	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—TAC1—atopic dermatitis	5.82e-05	0.000811	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—atopic dermatitis	5.81e-05	0.000809	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL22—atopic dermatitis	5.79e-05	0.000807	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCR3—atopic dermatitis	5.71e-05	0.000795	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL10—atopic dermatitis	5.69e-05	0.000792	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR3—atopic dermatitis	5.67e-05	0.00079	CbGpPWpGaD
Duloxetine—Nausea—Prednisone—atopic dermatitis	5.55e-05	0.000167	CcSEcCtD
Duloxetine—HTR2A—GPCR ligand binding—CCR5—atopic dermatitis	5.5e-05	0.000766	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT6—atopic dermatitis	5.49e-05	0.000764	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL5—atopic dermatitis	5.41e-05	0.000754	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCL5—atopic dermatitis	5.39e-05	0.000751	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL17—atopic dermatitis	5.33e-05	0.000743	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—atopic dermatitis	5.3e-05	0.000739	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NPS—atopic dermatitis	5.29e-05	0.000736	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—TAC1—atopic dermatitis	5.29e-05	0.000736	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL8—atopic dermatitis	5.2e-05	0.000724	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCR3—atopic dermatitis	5.18e-05	0.000722	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—PPARA—atopic dermatitis	5.16e-05	0.000719	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL27—atopic dermatitis	5.16e-05	0.000719	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR3—atopic dermatitis	5.15e-05	0.000717	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—TAC1—atopic dermatitis	5.05e-05	0.000704	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—NPS—atopic dermatitis	5.05e-05	0.000704	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	5.03e-05	0.0007	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCR3—atopic dermatitis	4.96e-05	0.00069	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL5—atopic dermatitis	4.91e-05	0.000684	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCL5—atopic dermatitis	4.9e-05	0.000682	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR5—atopic dermatitis	4.86e-05	0.000677	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR3—atopic dermatitis	4.76e-05	0.000663	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIF3A—atopic dermatitis	4.75e-05	0.000662	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL5—atopic dermatitis	4.7e-05	0.000655	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL17—atopic dermatitis	4.63e-05	0.000645	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL10—atopic dermatitis	4.61e-05	0.000643	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—TAC1—atopic dermatitis	4.59e-05	0.000639	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NPS—atopic dermatitis	4.59e-05	0.000639	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCR3—atopic dermatitis	4.5e-05	0.000627	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR5—atopic dermatitis	4.41e-05	0.000615	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—atopic dermatitis	4.37e-05	0.000608	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CMA1—atopic dermatitis	4.3e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL11—atopic dermatitis	4.3e-05	0.000599	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—atopic dermatitis	4.28e-05	0.000596	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL8—atopic dermatitis	4.27e-05	0.000595	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL5—atopic dermatitis	4.27e-05	0.000594	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TAC1—atopic dermatitis	4.24e-05	0.000591	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NPS—atopic dermatitis	4.24e-05	0.000591	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL10—atopic dermatitis	4.19e-05	0.000584	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCR3—atopic dermatitis	4.16e-05	0.000579	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIF3A—atopic dermatitis	4.13e-05	0.000575	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—atopic dermatitis	4.08e-05	0.000569	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—atopic dermatitis	4.06e-05	0.000566	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT6—atopic dermatitis	4.04e-05	0.000563	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL10—atopic dermatitis	4.01e-05	0.000558	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCL5—atopic dermatitis	3.97e-05	0.000553	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL5—atopic dermatitis	3.94e-05	0.000549	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL8—atopic dermatitis	3.83e-05	0.000533	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	3.81e-05	0.000531	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—MAPK8—atopic dermatitis	3.76e-05	0.000523	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CMA1—atopic dermatitis	3.73e-05	0.00052	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL11—atopic dermatitis	3.73e-05	0.00052	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL10—atopic dermatitis	3.64e-05	0.000507	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCL5—atopic dermatitis	3.61e-05	0.000502	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR5—atopic dermatitis	3.58e-05	0.000498	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT6—atopic dermatitis	3.51e-05	0.000489	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR3—atopic dermatitis	3.5e-05	0.000488	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GLB1—atopic dermatitis	3.49e-05	0.000486	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCL5—atopic dermatitis	3.45e-05	0.00048	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL10—atopic dermatitis	3.36e-05	0.000468	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ADSL—atopic dermatitis	3.35e-05	0.000466	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL8—atopic dermatitis	3.32e-05	0.000463	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	3.31e-05	0.000461	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—atopic dermatitis	3.25e-05	0.000453	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCL5—atopic dermatitis	3.13e-05	0.000436	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TAC1—atopic dermatitis	3.12e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NPS—atopic dermatitis	3.12e-05	0.000435	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—atopic dermatitis	3.11e-05	0.000433	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCR3—atopic dermatitis	3.06e-05	0.000427	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR3—atopic dermatitis	3.04e-05	0.000424	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GLB1—atopic dermatitis	2.96e-05	0.000412	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL8—atopic dermatitis	2.94e-05	0.000409	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL5—atopic dermatitis	2.9e-05	0.000404	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCL5—atopic dermatitis	2.89e-05	0.000403	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ADSL—atopic dermatitis	2.84e-05	0.000395	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—atopic dermatitis	2.82e-05	0.000393	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—atopic dermatitis	2.81e-05	0.000391	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NPS—atopic dermatitis	2.71e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TAC1—atopic dermatitis	2.71e-05	0.000378	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NGF—atopic dermatitis	2.68e-05	0.000373	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—atopic dermatitis	2.67e-05	0.000372	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR3—atopic dermatitis	2.66e-05	0.00037	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—atopic dermatitis	2.61e-05	0.000363	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—atopic dermatitis	2.55e-05	0.000355	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL5—atopic dermatitis	2.52e-05	0.000351	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL10—atopic dermatitis	2.48e-05	0.000345	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—atopic dermatitis	2.4e-05	0.000334	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKBIA—atopic dermatitis	2.21e-05	0.000308	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—atopic dermatitis	2.16e-05	0.000301	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.16e-05	0.0003	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL10—atopic dermatitis	2.15e-05	0.000299	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCL5—atopic dermatitis	2.13e-05	0.000297	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—atopic dermatitis	2.07e-05	0.000288	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NGF—atopic dermatitis	1.97e-05	0.000275	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—atopic dermatitis	1.96e-05	0.000274	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—atopic dermatitis	1.92e-05	0.000267	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—atopic dermatitis	1.88e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—atopic dermatitis	1.88e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCL5—atopic dermatitis	1.85e-05	0.000258	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—atopic dermatitis	1.8e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGF—atopic dermatitis	1.71e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—atopic dermatitis	1.71e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—atopic dermatitis	1.67e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—atopic dermatitis	1.63e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKBIA—atopic dermatitis	1.63e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—atopic dermatitis	1.58e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—atopic dermatitis	1.51e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—atopic dermatitis	1.5e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKBIA—atopic dermatitis	1.41e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK8—atopic dermatitis	1.39e-05	0.000193	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—atopic dermatitis	1.16e-05	0.000162	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARA—atopic dermatitis	1.13e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—atopic dermatitis	1.11e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—atopic dermatitis	1.1e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK8—atopic dermatitis	1.02e-05	0.000142	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—atopic dermatitis	1.01e-05	0.00014	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—atopic dermatitis	9.63e-06	0.000134	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARA—atopic dermatitis	9.6e-06	0.000134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—atopic dermatitis	9.58e-06	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK8—atopic dermatitis	8.86e-06	0.000123	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—atopic dermatitis	8.85e-06	0.000123	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—atopic dermatitis	6.52e-06	9.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—atopic dermatitis	5.66e-06	7.88e-05	CbGpPWpGaD
